Comprehensive Hereditary Cancer Risk Asessment
At our state-of-the-art, CLIA certified and COLA accredited facility we perform Next Generation Sequencing (NGS) based screening for mutations known to affect an individual’s risk of developing hereditary cancer. Results from the PREDICT™ test enable the physician to make better informed treatment decisions.
LabSolutions is pleased to offer its clients a comprehensive suite of genetic tests, allowing the physicians we serve to provide truly personalized healthcare. Coupling the latest in laboratory technologies with highly trained genomic scientists and counselors keeps our clients cutting edge. Next Generation Sequencing (NGS) based screening for mutations known to effect an individual’s risk of developing hereditary cancer is performed at our state-of-the-art, CLIA certified and COLA accredited facility. PREDICT™ test results, along with a treating provider’s expertise, are used to make better informed treatment and/or monitoring decisions.
Hereditary or Predisposition Cancer Genomics
Genetic testing looks for specific inherited changes (mutations) in a person’s genetic make-up. Genetic mutations may have multiple different effects on a patient’s health. Mutations that are harmful may increase a person’s chance, or risk, of developing a disease such as cancer. Inherited mutations are thought to play a role in 5-10% of all cancers. These particular conditions are considered hereditary and proper genetic testing may be used to determine an individual’s risk.
Some people inherit mutation(s) in the germline, allowing for the mutations to be passed on. There are two classes of cellular genes: oncogenes and tumor suppressor genes. Often, multiple genetic mutations in a single individual are responsible for the development of hereditary cancers.
Cancer is a disorder in which the normal control of cell growth is lost, causing abnormal proliferation of the affected cells. Inherited genetic mutations may increase a patient’s risk of developing cancer through numerous mechanisms, depending on the aberrant functions of the mutated parent gene. Mutations in genes involved in mismatched repair of damaged DNA are particularly susceptible to a higher cancer risk.
COMMON HEREDITARY CANCERS AND CANCER SYNDROMES
Lynch Syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
Colon Cancer (APC, BMPR1A, EPCAM)
Uterine Cancer (MLH1, MSH2, EPCAM, MSH6, PMS2)
Endometrial Cancer (EPCAM, MLH1, MSH2, MSH6)
Li-Fraumeni Syndrome (TP53)
Breast and Ovarian Cancer (BRCA1, BRCA2)
WHO SHOULD GET TESTED
BREAST CANCER GENETIC TESTING MAY BE APPRORIATE FOR YOU IF YOU HAVE A PERSONAL OR FAMILY HISTORY OF:
- Breast cancer diagnosed at age 45 or younger
- More than one cancer in the same person
- Ovarian, fallopian tube or primary peritoneal cancer at any age
- Male breast cancer at any age
- Three or more family members with breast, ovarian, pancreatic and/or prostate cancer
- Breast, uterine and thyroid cancer on the same side of the family
- Multiple members of the same side of the family with breast and other cancers
OVARIAN CANCER GENETIC TESTING MAY BE APPRORIATE FOR YOU IF YOU HAVE A PERSONAL OR FAMILY HISTORY OF:
- Ovarian cancer diagnosed at any age
- More than one cancer in the same person
- Three or more family members with ovarian, uterine, breast and/or colorectal cancer
- Multiple members of the same side of the family with ovarian cancers
COLORECTAL CANCER GENETIC TESTING MAY BE APPROPRIATE FOR YOU IF YOU HAVE A PERSONAL OR FAMILY HISTORY OF:
- Colorectal or uterine cancer diagnosed younger than age 50
- Two separate colorectal cancers or colorectal and uterine cancer in the same person
- Three or more family members with colorectal, uterine, ovarian and/or stomach cancer
- Multiple close family members with colorectal and other cancers
- Ten or more colorectal polyps during one’s lifetime
Genomic DNA from the submitted specimen is enriched for the complete coding regions and splice site junctions of genes assessed by PREDICT ™ using a proprietary targeted capture system developed by LabSolutions. All sequence alterations are described according to nomenclature guidelines set forth by the Human Genome Variation Society (HGVS). Benign and likely benign variants, if present, are not reported but are available upon request.